← All Stocks

ResMed Inc.

RMD · NYQ
$222.00+4.96%
52W Low: $180.2752W High: $284.87
Current: $222.00  ·  40% of 52-week range
HealthcareMedical Instruments & SuppliesNYQ
View live charts, options flow & technicals for ResMed Inc. → Open Dashboard

ResMed Inc. (RMD) is a healthcare company in the medical instruments & supplies industry with $5.65B in trailing revenue trading at a 21.3× trailing P/E — analyst consensus: buy.

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Key Statistics

Market Cap$32.02B
Revenue (TTM)$5.65B
EPS (TTM)$10.43
EPS (Fwd est.)$13.23
Employees11,370
Trailing P/E21.28
Forward P/E16.78
PEG Ratio1.29
Price / Sales5.66
Price / Book4.86
EV / EBITDA14.97
Beta (5Y)0.77

Analyst Consensus

Consensus
Buy
Analyst Price Target
+12.7% upside
Target: $250.22

Annual Revenue & Net Income

RevenueNet Income
'23
$4.22B
$900.00M
'24
$4.69B
$1.02B
'25
$5.15B
$1.40B
'26
$5.65B
$1.52B

Earnings History


QuarterActual EPSEstimateResult
Aug 2026
$2.95
$2.89Beat (+2.0%)
Apr 2026
$2.86
$2.80Beat (+2.1%)
Jan 2026
$2.81
$2.72Beat (+3.1%)
Oct 2025
$2.55
$2.50Beat (+2.0%)

Next Earnings Report

ResMed Inc. is next expected to report earnings on 29 Oct 2026.

Profitability

61.6%
30.9%
26.9%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)8.6%
Return on Equity24.3%
Return on Assets14.0%

Balance Sheet

Cash & Equivalents$1.47B
Total Debt$830.00M
Net Position$640.00M (net cash)
Free Cash Flow (TTM)$940.00M
Debt / Equity12.54

Share Ownership

Institutions 71.2%
Insiders 0.5%
Public 28.3%

Dividend

Annual Rate
$2.64
Yield
1.19%
Payout Ratio
23.0%
Ex-Dividend Date
20 Aug 2026
5Y Avg Yield
0.88%

Related Stocks

LLYUNHJNJMRKABBVTMOPFEISRG

Frequently Asked Questions

What does ResMed Inc. (RMD) do?
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that …
What is RMD's market cap?
ResMed Inc. has a market capitalization of approximately $32.02B.
What is RMD's P/E ratio?
ResMed Inc. trades at a trailing P/E ratio of 21.3x and a forward P/E of 16.8x, which is below the broad market average of ~25x.
How much revenue does RMD generate?
ResMed Inc. generated $5.65B in trailing 12-month revenue.
What do analysts say about RMD?
The analyst consensus rating for ResMed Inc. is buy, with a mean price target of $250.22. That implies +12.7% upside from the current price.
When does RMD report earnings?
ResMed Inc. is next scheduled to report earnings on 29 Oct 2026.
Does RMD pay a dividend?
Yes. ResMed Inc. pays a dividend with a current yield of 1.19%, at an annual rate of $2.64 per share.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for ResMed Inc. on Apsis Markets.

Open Live Dashboard →